Human chorionic gonadotrophin for threatened miscarriage
- 12 May 2010
- journal article
- research article
- Published by Wiley in Emergencias
- No. 5,p. CD007422
- https://doi.org/10.1002/14651858.cd007422.pub2
Abstract
Miscarriage is a common occurrence in early pregnancy. Human chorionic gonadotrophin (hCG) is secreted by the syncytiotrophoblast. It promotes the corpus luteum to secrete progesterone and helps in maintaining the pregnancy. Hence, there has been much interest in the use of hCG to treat threatened miscarriage. To assess the efficacy and safety of human chorionic gonadotropins in the treatment of threatened miscarriage. We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (February 2010), the Cochrane Central Register of Controlled Trials (The Cochrane Library 2010, Issue 1), MEDLINE (1966 to 12 February 2010), EMBASE (1980 to 12 February 2010) and CINAHL (1989 to 12 February 2010). We also scanned the bibliographies of all located articles for any unidentified articles and attempted to contact authors where necessary. All randomised controlled trials (RCTs) that assess the effectiveness of hCG in the treatment of threatened miscarriage compared to placebo, no treatment of any other intervention, provided viability of the fetus has been confirmed by ultrasound before the commencement of treatment. At least two authors assessed the trials for inclusion in the review and extracted the data. Three studies (312 participants) were included in the review, one of which was of poor methodological quality. The meta-analysis showed that there was no statistically significant difference in the incidence of miscarriage between hCG and 'no hCG' (placebo or no treatment) groups (Risk ratio (RR) 0.66; 95% confidence interval (CI) 0.42 to 1.05). When hCG and bed rest alone were compared, there was a significant reduction in the risk of miscarriage (RR 0.47; 95% CI 0.27 to 0.82). This result should be interpreted with caution, as one of the two trials from which this result is derived was of poor methodological quality. There was no report of adverse effects of hCG on mother or baby. More good quality RCTs are urgently needed to assess the effects of hCG in threatened miscarriage. The current evidence does not support the routine use of hCG in the treatment of threatened miscarriage.Keywords
This publication has 21 references indexed in Scilit:
- No effect of human chorionic gonadotropin treatment due to threatened abortion in early pregnancy for birth outcomesOpen Medicine, 2008
- Recurrent miscarriageThe Lancet, 2006
- First trimester threatened miscarriage treatment with human chorionic gonadotrophins: a randomised controlled trialBJOG: An International Journal of Obstetrics and Gynaecology, 2005
- Cytogenetic analyses of culture failures by comparative genomic hybridisation (CGH)–Re-evaluation of chromosome aberration rates in early spontaneous abortionsEuropean Journal of Human Genetics, 2001
- Maternal age and fetal loss: population based register linkage studyBMJ, 2000
- Spontaneous Abortions and Major Malformations in Women with Diabetes MellitusSeminars in Reproductive Medicine, 1999
- Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies)BMJ, 1997
- Abnormal bacterial colonisation of the genital tract and subsequent preterm delivery and late miscarriageBMJ, 1994
- Human chorionic gonadotrophin (hCG) in the management of recurrent abortion; results of a multi-centre placebo-controlled studyEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 1992
- Perinatal outcome of pregnancies complicated by vaginal bleedingBJOG: An International Journal of Obstetrics and Gynaecology, 1992